Publikationen von 0000-0001-8390-6315
(ORCID: 0000-0001-8390-6315)

Pal, Sumanta K., Somford, Diederik M., Grivas, Petros, Sridhar, Srikala S., Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P., Andresen, Corina, Schnabel, Marco J., Cole, Suzanne und Daneshmand, Siamak (2022) Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology 18 (21), S. 2599-2614. Volltext nicht vorhanden.